These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 15709162)

  • 1. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches.
    Suggitt M; Bibby MC
    Clin Cancer Res; 2005 Feb; 11(3):971-81. PubMed ID: 15709162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.
    Kelland LR
    Eur J Cancer; 2004 Apr; 40(6):827-36. PubMed ID: 15120038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hollow fibre model in cancer drug screening: the NCI experience.
    Decker S; Hollingshead M; Bonomi CA; Carter JP; Sausville EA
    Eur J Cancer; 2004 Apr; 40(6):821-6. PubMed ID: 15120037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The preclinical new drug research program of the National Cancer Institute.
    Driscoll JS
    Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Preclinical evaluation of anticancer drugs: a model remaining a model!].
    Lavelle F
    Bull Cancer; 1998 Oct; 85(10):837-42. PubMed ID: 9835860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mighty mouse: genetically engineered mouse models in cancer drug development.
    Sharpless NE; Depinho RA
    Nat Rev Drug Discov; 2006 Sep; 5(9):741-54. PubMed ID: 16915232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening and evaluation of anticancer agents.
    Zee-Cheng RK; Cheng CC
    Methods Find Exp Clin Pharmacol; 1988 Feb; 10(2):67-101. PubMed ID: 3283480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in molecular carcinogenesis: current and future use of mouse models to screen and validate molecularly targeted anticancer drugs.
    Frijhoff AF; Conti CJ; Senderowicz AM
    Mol Carcinog; 2004 Apr; 39(4):183-94. PubMed ID: 15057870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetically engineered models have advantages over xenografts for preclinical studies.
    Becher OJ; Holland EC
    Cancer Res; 2006 Apr; 66(7):3355-8, discussion 3358-9. PubMed ID: 16585152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development.
    Peterson JK; Houghton PJ
    Eur J Cancer; 2004 Apr; 40(6):837-44. PubMed ID: 15120039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer drug development at the US National Cancer Institute.
    Takimoto CH
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S29-33. PubMed ID: 12819935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on NCI in vitro drug screen utilities.
    Holbeck SL
    Eur J Cancer; 2004 Apr; 40(6):785-93. PubMed ID: 15120034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The contemporary drug development process: advances and challenges in preclinical and clinical development.
    Garrett MD; Walton MI; McDonald E; Judson I; Workman P
    Prog Cell Cycle Res; 2003; 5():145-58. PubMed ID: 14593708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic assays for screening anticancer agents.
    Baharith LA; Al-Khouli A; Raab GM
    Stat Med; 2006 Jul; 25(13):2323-39. PubMed ID: 16013035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Models of metastasis in drug discovery.
    Talmadge JE
    Methods Mol Biol; 2010; 602():215-33. PubMed ID: 20012401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen.
    Yip KW; Mao X; Au PY; Hedley DW; Chow S; Dalili S; Mocanu JD; Bastianutto C; Schimmer A; Liu FF
    Clin Cancer Res; 2006 Sep; 12(18):5557-69. PubMed ID: 17000693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemical evaluation by cancer cell line panel and its role in molecular target-based anticancer drug screening].
    Yamori T
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):485-90. PubMed ID: 15114687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development.
    Hansen K; Khanna C
    Eur J Cancer; 2004 Apr; 40(6):858-80. PubMed ID: 15120042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute.
    Christian MC; Pluda JM; Ho PT; Arbuck SG; Murgo AJ; Sausville EA
    Semin Oncol; 1997 Apr; 24(2):219-40. PubMed ID: 9129691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.